Quick Takeaways
- Deep Track Capital, LP filed SCHEDULE 13G/A for Tarsus Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (TARS).
- Disclosed ownership: 7.1%.
- Date of event: 30 Sep 2025.
Deep Track Capital, LP - 30 Sep 2025 SCHEDULE 13G/A Report for Tarsus Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (TARS)
- Filing Manager
- Deep Track Capital, LP
- Reporting Manager
- Deep Track Capital, LP
- Symbol
- TARS
- Shares outstanding
- 42,194,093 shares
- Disclosed Ownership
- 3,000,000 shares
- Ownership
- 7.1%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 08:23:52 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 28 Jul 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Deep Track Capital, LP disclosed 7.1% ownership in Tarsus Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (TARS) on 30 Sep 2025."
What Changed
- Previous schedule filing date: 28 Jul 2025.
- Current filing was accepted on 14 Nov 2025, 08:23.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 7.1% | 3,000,000 | 0 | 3,000,000 | /s/ David Kroin | David Kroin, Managing Member of the General Partner of the Investment Adviser | |
| Deep Track Biotechnology Master Fund, Ltd. | 7.1% | 3,000,000 | 0 | 3,000,000 | /s/ David Kroin | David Kroin, Director | |
| David Kroin | 7.1% | 3,000,000 | 0 | 3,000,000 | /s/ David Kroin | David Kroin |